Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMS6D3)

• Drug Name: IN-1166 Drug Info
• Synonyms: UNII-86NAB50A9A; IN-1166; CHEMBL387748; 86NAB50A9A; SCHEMBL373674; BDBM50214857; Benzonitrile, 3-(((5-(6-methyl-2-pyridinyl)-4-(6-quinoxalinyl)-1H-imidazol-2-yl)methyl)amino)-; 945244-71-3

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 16654987
  CAS Number: CAS 945244-71-3
  TTD Drug ID: DMMS6D3

Molecule-Related Drug Atlas

Drug(s) Targeting JNK2 messenger RNA (JNK2 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide	DMUFVM6	Discovery agent	N.A.	Investigative	[3]
AS-601245	DMQ95EB	Discovery agent	N.A.	Investigative	[4]
Aminopyridine deriv. 2	DM94KQP	Discovery agent	N.A.	Investigative	[3]
N-(4-amino-5-cyano-6-ethoxypyridin-2-yl)acetamide	DMY1FMG	Discovery agent	N.A.	Investigative	[3]
JNK-IN-8	DMLWYJB	Discovery agent	N.A.	Investigative	[5]
N-(4-amino-6-butoxy-5-cyanopyridin-2-yl)acetamide	DMSAD87	Discovery agent	N.A.	Investigative	[3]
AC1LG8KT	DMFKV97	Discovery agent	N.A.	Investigative	[6]
ISIS 18078	DMHZPJ0	Solid tumour/cancer	2A00-2F9Z	Investigative	[7]

Drug(s) Targeting TGF-beta receptor type I (TGFBR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LY2157299	DMP8HW1	Arteriosclerosis	BD40	Phase 2/3	[8]
TEW-7197	DM2LBC3	Myeloproliferative neoplasm	2A20	Phase 2	[9]
Metelimumab	DMENFD6	Scleroderma	4A42	Phase 1/2	[10]
TP-0184	DMJVZBC	Solid tumour/cancer	2A00-2F9Z	Phase 1	[11]
P-2745	DMJ3PNS	Chronic myelogenous leukaemia	2A20.0	Phase 1	[12]
LY3200882	DMQP6VB	Solid tumour/cancer	2A00-2F9Z	Phase 1	[13]
PF-06952229	DMDQJEZ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[14]
SB-431542	DM0YOXQ	Pulmonary fibrosis	CB03.4	Preclinical	[15]
SM-16	DMHXJV2	Fibrosis	GA14-GC01	Terminated	[16]
LF-984	DMIYMS2	Fibrosis	GA14-GC01	Terminated	[17]

Drug(s) Targeting Stress-activated protein kinase 2a (p38 alpha)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ozagrel	DMIGKA1	Xerophthalmia	5B55.Y	Phase 4	[18]
Losmapimod	DMIL37Z	Acute coronary syndrome	BA41	Phase 3	[18]
VX-702	DMKJDR6	Coronary artery disease	BA80	Phase 2a	[19]
VX-745	DMJAEG6	Alzheimer disease	8A20	Phase 2	[20]
Dilmapimod	DMBYJ92	Acute lung injury	NB32.3	Phase 2	[18]
PMID25991433-Compound-A1	DM89LF0	N. A.	N. A.	Patented	[21]
PMID25991433-Compound-F2	DM37VIQ	N. A.	N. A.	Patented	[21]
PMID25991433-Compound-L2	DM58UO9	N. A.	N. A.	Patented	[21]
PMID25991433-Compound-L3	DM3LWUR	N. A.	N. A.	Patented	[21]
PMID25991433-Compound-L1	DM2135Y	N. A.	N. A.	Patented	[21]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
JNK2 messenger RNA (JNK2 mRNA)	TT3IVG2	MK09_HUMAN	Inhibitor	[2]
Stress-activated protein kinase 2a (p38 alpha)	TTQBR95	MK14_HUMAN	Inhibitor	[1]
TGF-beta receptor type I (TGFBR1)	TTP4520	TGFR1_HUMAN	Inhibitor	[2]

References

• [1] Synthesis and biological evaluation of trisubstituted imidazole derivatives as inhibitors of p38alpha mitogen-activated protein kinase. Bioorg Med Chem Lett. 2008 Jul 15;18(14):4006-10.
• [2] Synthesis and biological evaluation of 4(5)-(6-alkylpyridin-2-yl)imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors. J Med Chem. 2007 Jun 28;50(13):3143-7.
• [3] Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem. 2006 Jun 15;49(12):3563-80.
• [4] The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
• [5] Discovery of potent and selective covalent inhibitors of JNK. Chem Biol. 2012 Jan 27;19(1):140-54.
• [6] N-(3-Cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)amides as potent, selective, inhibitors of JNK2 and JNK3. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1296-301.
• [7] US patent application no. 7,425,545, Modulation of C-reactive protein expression.
• [8] Cardiac Safety of TGF-beta Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study. Cardiovasc Toxicol. 2015 Oct;15(4):309-23.
• [9] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [10] Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov. 2004 Dec;3(12):1011-22.
• [11] Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma.
• [12] Novel potent inhibitor of Bcr-Abl mutated imatinib resistant chronic myeloid leukemia cell lines. Cancer Research. 06/2012; 72(8 Supplement):1822-1822.
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [14] Targeting the TGF pathway for cancer therapy. Pharmacol Ther. 2015 Mar;147:22-31.
• [15] Pyrazolone based TGFbetaR1 kinase inhibitors. Bioorg Med Chem Lett. 2010 Jan 1;20(1):326-9.
• [16] TGF-beta type I receptor kinase inhibitor down-regulates rheumatoid synoviocytes and prevents the arthritis induced by type II collagen antibody. Int Immunol. 2007 Feb;19(2):117-26.
• [17] US patent application no. 2013,0028,978, Compositions and methods for wound treatment.
• [18] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [19] Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009 May;60(5):1232-41.
• [20] Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.
• [21] c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.